Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

被引：4
|
作者：
Mok, Tony
Cheng, Ying
Zhou, Xiangdong
Lee, Ki Hyeong
Nakagawa, Kazuhiko
Niho, Seiji
Tsuji, Fumito
Rosell, Rafael
Jaime, Jesus Corral
Migliorino, Maria Rita
Pluzanski, Adam
Linke, Rolf Gerhard
Sbar, Eric
Wang, Tao
Wu, Yi-Long
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[2] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
[3] Third Mil Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[4] Chungbuk Natl Univ Hosp, Chungcheong, South Korea
[5] Kinki Univ, Fac Med, Osakasayama, Japan
[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[7] SFJ Pharmaceut Grp Inc, Osaka, Japan
[8] Catalan Inst Oncol, Barcelona, Spain
[9] Hosp Virgen Rocio, Seville, Spain
[10] Azienda Osped San Camilo Forlanini, Rome, Italy
[11] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[12] Inst Oncol, Warsaw, Poland
[13] SFJ Pharmaceut Inc, Pleasanton, CA USA
[14] Pfizer Inc, Collegeville, PA USA
[15] Pfizer Inc, Groton, CT 06340 USA
[16] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[17] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 18期
关键词：
D O I：
10.1200/JCO.2017.35.18_suppl.LBA9007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9007
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase Ilb trial LUX-Lung 7
    O'Byrne, K. J.
    Park, K.
    Tan, E.
    Zhang, L.
    Hirsh, V.
    Boyer, M.
    Yang, J. C.
    Mok, T.
    Kim, M.
    Massey, D.
    Zazulina, V.
    Paz-Ares, L.
    LUNG CANCER, 2016, 91 : S25 - S25
  • [42] Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first line therapy for advanced non-small cell lung cancer (NSCLC)
    Weissman, C. H.
    Reynolds, C. H.
    Neubauer, M. A.
    Steinberg, I.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Dwan, Kerry
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Jain, Pooja
    Green, John A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (05):
  • [44] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    LUNG CANCER, 2010, 67 (03) : 348 - 354
  • [45] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Chaplin, Marty
    Green, John A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (03):
  • [46] COST-UTILITY ANALYSIS OF GEFITINIB AND EGFR MUTATION TESTING AS THE FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER IN VIETNAM
    Tran, T. T.
    VALUE IN HEALTH, 2017, 20 (05) : A112 - A112
  • [47] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [48] A Phase Ⅱ Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China
    Lu Yang 1
    1Department of Thoracic Medical Oncology
    ChineseJournalofCancerResearch, 2010, 22 (01) : 1 - 9
  • [49] BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Gridelli, Cesare
    Rossi, Antonio
    Ciardiello, Fortunato
    De Marinis, Filippo
    Crino, Lucio
    Morabito, Alessandro
    Morgillo, Floriana
    Montanino, Agnese
    Daniele, Gennaro
    Piccirillo, Maria Carmela
    Normanno, Nicola
    Gallo, Ciro
    Perrone, Francesco
    CLINICAL LUNG CANCER, 2016, 17 (05) : 461 - 465
  • [50] First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
    Huang, L. -y.
    Chang, H. -p.
    Chang, R. -y.
    Tai, H. -y.
    Huang, Y. -w.
    Lee, P. -c.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (20) : 7632 - 7640
12345